Full Press Release Details
Announces First Two Patients in Hong Kong
Successfully Treated with CGuard EPS
Aviv, Israel-May 30, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"),
a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the
first two patients in Hong Kong have been successfully treated with CGuard EPS. The two cases were conducted on patients
with carotid artery stenosis at St. Teresa Hospital by Dr. PW Cheng and Dr. YW Chow, a leading neurointerventional radiologist
and leading cardiologist, respectively.
first cases in Hong Kong follow the previously announced distribution agreement for CGuard EPS with a distribution partner
in Hong Kong that was announced two months ago. These are the first cases performed in the Asia Pacific region and represent a
further milestone for InspireMD's global expansion strategy.
PW Cheng and Dr. YW Chow commented, "These procedures went seamlessly and we are very pleased with the way CGuard performed.
We are very excited to have access to this innovative technology as it provides vastly superior safety to carotid artery stenting
(CAS) patients compared to conventional stents. We envision this procedure becoming the standard of care for carotid stenting
Gago, EVP and Chief Commercial Officer of InspireMD, commented, "We are pleased to report another milestone in the continued
execution of our growth strategy in the Asia Pacific region. Dr. Cheng and Dr. Chow are among the top physicians in Hong Kong
in their respective fields, further illustrating our ability to attract the top key opinion leaders around the world. We look
forward to announcing further progress in the Asia Pacific region over the coming months."
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard ), neurovascular, and peripheral
artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR and certain warrants
are quoted on the NYSE MKT under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.